Search Results 1841-1850 of 19630 for Hemoglobin

1. Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer - Mayo Clinic

   Platelet count > 100,000/mm^3; Hemoglobin > 9.0 g/dL; Total bilirubin ≤ 1.5 x upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate amino ...

2. Pilot Study Of Duodenal Mucosal RF Vapor Ablation In US Subjects With Type-2 Diabetes Mellitus - Mayo Clinic

   Persistent anemia, defined as hemoglobin <10g/dl. Significant cardiovascular disease, including known history of valvular disease, or myocardial infarction ...

3. A Study Evaluating AMG 424 in Subjects With Multiple Myeloma - Mayo Clinic

   Hemoglobin > 8.0 g/dL (> 80 g/L). Use of erythropoietic stimulating factors and red blood cell (RBC) transfusions per institutional guidelines is allowed ...

4. T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer - Mayo Clinic

   - Hemoglobin >= 8 g/dL (Note: packed red blood cells [PRBC] transfusion is not permitted to achieve eligibility) - Platelet count >= 100,000/mm^3 - ...

5. Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L Biliary Tract Cancer (BTC) - Mayo Clinic

   ... hemoglobin (Hgb) ≥ 9 g/dL (participants may have been transfused) at study entry and at Week 1 Day 1 prior to dosing. Previously transfused participants ...

6. Study to Evaluate the Safety and Effectiveness of BMS-986036 in Adults with Nonalcoholic Steatophepatitis (NASH) and Compensated Liver Cirrhosis - Mayo Clinic

   Hemoglobin A1c ≥ 10%;; Fasting TGs > 500 mg/dL;; Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 according to the Modification of Diet in ...

7. A Study to Evaluate Cellular Senescence with Senolytics to Improve Skeletal Health in Older Humans - Mayo Clinic

   Subjects who are Type II diabetic and on insulin due to a risk of hypoglycemia. Hemoglobin A1c ≥ 8.0% at screening; Abnormal screening labs (see below):.

8. FAQ - eMERGE Genome Informed Risk Assessment - Mayo Clinic Research

   Clinical risk factors include the most recent hemoglobin A1C, reported physical activity and body mass index (BMI). How does the eMERGE study define 'high ...

9. A Study to Compare the Effectiveness and Safety of Emixustat Hydrochloride with Placebo to Treat Macular Atrophy Secondary to Stargadt Disease - Mayo Clinic

   Impaired hematologic function: hemoglobin < 11 g/dL; neutrophil count < 1.6 × 109/L; or platelet count < 100 × 109/L. Any laboratory screening test that ...

10. Deucravacitinib (BMS-986165) in LPP and FFA - Mayo Clinic

    ... hemoglobin < 10 g/dL (100.0 g/L); total white blood cell count < 3000 cells/μL (< 3.00 x 10^3/μL or < 3.00 billion/L); neutropenia (absolute neutrophil ...